Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. executive Jordan Zeik Silverstein, Head of Strategy, reported his beneficial holdings of the company’s securities. The filing lists multiple stock option awards over Ordinary Shares at exercise prices ranging from $1.1700 to $11.0000, with expirations from 2028 through 2036, alongside 50,000 restricted stock units and 7,826 Ordinary Shares held directly. Footnotes explain that one option grant is fully vested and others, as well as the RSUs, vest in scheduled installments over several years.
Immatics N.V. director and Chief Executive Officer Harpreet Singh Jasuja filed an initial ownership report showing a mix of ordinary shares, stock options and restricted stock units. He directly holds 217,241 ordinary shares and multiple option grants over ordinary shares with exercise prices ranging from $1.06 to $11.00, plus 167,500 RSUs that each convert into one ordinary share as they vest over time.
Immatics N.V. director Alise Reicin reported existing holdings of stock options in the company. The filing shows options to buy 60,000 ordinary shares at an exercise price of $12.08 per share, expiring on July 28, 2034, vesting in 12 equal quarterly installments over 36 months from the grant date of July 29, 2024. It also lists options to buy 41,500 ordinary shares at an exercise price of $5.44 per share, expiring on June 23, 2035, which vest 100% on the first anniversary of the grant date, June 24, 2025. These entries describe current derivative holdings rather than new open‑market purchases or sales.
Immatics N.V. reported the initial beneficial ownership of its Chief Financial Officer, Ramanan Venkat, in a Form 3. He holds a stock option to buy 350,000 ordinary shares at an exercise price of $9.0000 per share, expiring on September 30, 2035.
These options vest 25% on the first anniversary of the grant date, October 1, 2025, with the remaining 75% vesting in 12 equal quarterly installments over the following three years. The filing shows this option position as a direct holding and does not report any open-market buying or selling activity.
Immatics N.V. director Eliot Forster reported his initial holdings of stock options on a Form 3. The filing lists several option grants giving him the right to buy Immatics ordinary shares at exercise prices between $5.44 and $12.00, with expirations from 2030 through 2035.
According to the footnotes, some of these options are already fully vested, while others vest 100% on the first anniversary of their grant date on June 24, 2025. All positions shown are direct holdings and represent unexercised options, not recent market purchases or sales.
Immatics N.V. Chief People Officer Amie Elizabeth Krause reported her initial ownership of stock options in the company. The filing shows a stock option to buy ordinary shares at an exercise price of $10.58 per share, covering 211,000 underlying ordinary shares.
The options vest 25% on the first anniversary of the grant date, October 27, 2025, and then continue vesting in 12 equal quarterly installments over the following three years, and expire on October 26, 2035. This Form 3 does not reflect any buy or sell transaction, only existing derivative holdings.
Immatics N.V. director Heather L. Mason filed an initial ownership report listing existing stock option awards over the company’s ordinary shares. She holds several options with exercise prices such as 5.4400 and 12.0000 per share, expiring between 2030 and 2035. Some options are already fully vested, while others vest 100% on June 24, 2025, highlighting her long-term equity-based compensation. The filing reports holdings only and does not show any new purchases or sales.
Immatics N.V. director Carter Paul Rutherford filed an initial statement of beneficial ownership showing several stock options over ordinary shares. The options cover blocks such as 25,000 underlying shares at an exercise price of $10.0000 expiring on June 30, 2030, and 15,000 underlying shares at $11.0000 expiring on December 8, 2031. Additional options include 25,000 underlying shares at $7.9400 expiring on June 13, 2032, 25,000 at $11.4100 expiring on June 26, 2033, 40,000 at $12.0000 expiring on June 24, 2034, and 41,500 at $5.4400 expiring on June 23, 2035. Footnotes state that certain options are already fully vested and others vest 100% on the first anniversary of the June 24, 2025 grant date.
Immatics N.V. director Adam Leo Stone has filed an initial Form 3 showing his stock option holdings in the company. The filing lists several options to buy Immatics ordinary shares with exercise prices of $10.0000, $11.0000, $7.9400, $11.4100, $12.0000, and $5.4400, expiring between June 30, 2030 and June 23, 2035.
Each option relates to a specific number of underlying ordinary shares, including 25,000, 15,000, 25,000, 25,000, 40,000 and 41,500 shares, all held directly. According to the footnotes, some of these options are already fully vested, while others are scheduled to vest 100% on June 24, 2025.
Immatics N.V. Chief Operating Officer Walter Steffen Martin reported his current equity holdings in the company. The filing lists multiple stock option grants over several years, including options on 200,000 ordinary shares at an exercise price of 9.3200 per share expiring on January 7, 2036. It also shows 50,000 restricted stock units, each convertible into one ordinary share, and 10,000 ordinary shares held directly. All entries are reported as direct ownership with no buy or sell transactions indicated.